Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic

Abstract

Enzalutamide has clinical activity in breast cancer as a single agent and in combination with exemestane. Activity is seen in both triple negative AR BC and also ER AR BC. Clinical data in Her2 AR BC is too immature to make conclusions. The proposed clinical trials for Years 3-5 appear to be justified based on clinical activity and the current preclinical data.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2016
Accession Number
AD1032758

Entities

People

  • Anthony D Elias

Organizations

  • University of Colorado Denver

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Acquisition
  • Androgen Receptors
  • Androgens
  • Biomedical Research
  • Breast Cancer
  • Clinical Trials
  • Department Of Defense
  • Diseases And Disorders
  • Hormones
  • Inhibitors
  • Neoplasms
  • Pilot Studies
  • Prostate Cancer
  • Proteins
  • Targeting
  • Therapy

Fields of Study

  • Chemistry
  • Medicine
  • Physics

Readers

  • Neurodegenerative Parkinson's Disease and Rickettsial Disease handbook, including the data level of dopamine, BC, neurons, and PD.
  • Prostate Cancer Biology.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.